TAO Synergies (TAOX) Operating Expenses (2019 - 2026)
TAO Synergies' (TAOX) quarterly Operating Expenses came in at $1.7 million in Q2 2026, down 45.46% on a YoY basis from $3.0 million in Q2 2025, and down 2.85% quarter-over-quarter from $1.7 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Operating Expenses (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Operating Expenses for 8 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Expenses fell 45.46% year-over-year to $1.7 million; the trailing twelve-month figure through Jun 2026 stood at $8.6 million (up 12.48% YoY), and the FY2025 full-year result was $9.3 million, up 37.23% from the prior year.
- Operating Expenses eased to $1.7 million in Q2 2026 per TAOX's latest filing, from $1.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $5.9 million in Q4 2022 and bottomed at $1.1 million in Q1 2025.
- Historically, Operating Expenses has averaged $2.4 million across 5 years, with a median of $2.0 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses plunged 63.79% in 2023, then jumped 107.3% in 2025.
- Over 5 years, Operating Expenses stood at $5.9 million in 2022, then slumped by 63.79% to $2.1 million in 2023, then retreated by 26.83% to $1.6 million in 2024, then surged by 107.3% to $3.2 million in 2025, then slumped by 48.74% to $1.7 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.7 million, $1.7 million, and $3.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | 367.83 Mn |
| 10 | TAO Synergies | 30.56 Mn | 30.56 Mn | - | 1.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 3.23 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 3.04 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 2.13 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 2.92 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | 3.17 Mn |
| Jun 30, 2022 | 3.80 Mn |
| Mar 31, 2022 | 3.28 Mn |
| Dec 31, 2021 | 4.24 Mn |
| Sep 30, 2021 | 2.93 Mn |